CN107325114B - A kind of preparation method of Ceftaroline Fosamil intermediate - Google Patents

A kind of preparation method of Ceftaroline Fosamil intermediate Download PDF

Info

Publication number
CN107325114B
CN107325114B CN201710537327.6A CN201710537327A CN107325114B CN 107325114 B CN107325114 B CN 107325114B CN 201710537327 A CN201710537327 A CN 201710537327A CN 107325114 B CN107325114 B CN 107325114B
Authority
CN
China
Prior art keywords
reaction
organic solvent
chlorine
cephalo
ceftaroline fosamil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710537327.6A
Other languages
Chinese (zh)
Other versions
CN107325114A (en
Inventor
杨琨
宋立明
许文革
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Province Ainuode Biological Engineering Co Ltd
Original Assignee
Jilin Province Ainuode Biological Engineering Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin Province Ainuode Biological Engineering Co Ltd filed Critical Jilin Province Ainuode Biological Engineering Co Ltd
Priority to CN201710537327.6A priority Critical patent/CN107325114B/en
Publication of CN107325114A publication Critical patent/CN107325114A/en
Application granted granted Critical
Publication of CN107325114B publication Critical patent/CN107325114B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention provides a kind of preparation methods of Ceftaroline Fosamil intermediate, comprising the following steps: under radical initiator catalysis, condensation reaction occurs for 3- chlorine cephalo and 4- (4- pyridyl group) -2- thyroidan, then quaternization reaction occurs, and obtains pyridiniujm;Then it is deprotected with one kettle way, obtains Ceftaroline Fosamil intermediate.Compared with prior art, the present invention is using 3- chlorine cephalo as initial reactant, to apply for the first time;3- chlorine cephalo and the condensation reaction of 4- (4- pyridyl group) -2- thyroidan are catalyzed by radical initiator, and reaction safety, processing is convenient, belongs to environmental-friendly reaction type, while the reaction greatly reduces the generation of isomers;The protecting group for removing 4 and 7 simultaneously using one kettle way, to enormously simplify reaction process, and improves the quality of reaction yield and product.The synthetic method has simple process, without harsh reaction condition the advantages that, be very suitable to industrialized production.

Description

A kind of preparation method of Ceftaroline Fosamil intermediate
Technical field
The invention belongs to cephalo-type medicine intermediate preparation fields, and in particular to a kind of preparation of Ceftaroline Fosamil intermediate Method.
Background technique
Ceftaroline is the 5th generation cephalosporin analog antibiotic, is to be obtained by forth generation cephalosporin Cefozopran derivative, by day The exploitation of this Takeda Pharmaceutical Company Limited, ForestLaborstories company, the U.S. obtain market authorization, obtain on October 29th, 2010 U.S. FDA approval listing is obtained, for treating the acquired bacillary enteritis in Adults Community, acute bacterial skin and soft tissue sense Dye, including infection caused by MRSA.Ceftaroline Fosamil is the pro-drug of ceftaroline, increases its stability, in vivo can It is hydrolyzed to ceftaroline rapidly and plays drug effect.Ceftaroline Fosamil to most of gram-negative bacteria, Grain-negative anaerobic bacteria and Grain-positive anaerobic bacteria have stronger antibacterial activity, and its adverse reaction with other cephalosporins compared with relatively gently, safety compared with It is good.
7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride is head The key intermediate of spore Lorraine ester, often referred to simply as ceftaroline intermediate parent nucleus.Existing literature (Bioorg&Med.Chem.11 (2003), 2427-2437) and patent report all using 3- hydroxy-cepham as starting material.The priming reaction of 3- hydroxy-cepham can be led The appearance for causing S-3 isomers, to substantially reduce the yield of reaction and the quality of product.
Summary of the invention
The present invention provides a kind of preparation methods of Ceftaroline Fosamil intermediate, are catalyzed 3- chlorine head using radical initiator Condensation reaction occurs for spore and 4- (4- pyridyl group) -2- thyroidan, obtains pyridiniujm by methylation reaction;Then one is utilized Pot method removes 4 and 7 protecting groups simultaneously, obtains Ceftaroline Fosamil intermediate.
Specific reaction step is as follows:
Step 1) is in nonpolar solvent A, under radical initiator catalysis, 3- chlorine cephalo and 4- (4- pyridyl group) -2- Condensation reaction occurs for thyroidan;The peak area of 3- chlorine cephalo is stirred to react into HPLC less than 0.2%, reaction solution is concentrated into It is cooled to low temperature after half volume, filters the crystal of precipitation;It is washed with organic solvent B, it is dry, obtain 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate hydrochloride;
Step 2) reacts the product of step 1) with methylating reagent, obtains 7- phenylacetylamino -3- [4- (1- methyl -4- Pyridine) -2- thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate iodide;
The product that step 3) obtains step 2) is dissolved in organic solvent C, phosphorus pentachloride is added, in inert gas shielding Under, organic base is added dropwise under cryogenic conditions, after fully reacting, then is cooled to -40 DEG C, vicinal diamines, fully reacting is slowly added dropwise Afterwards;Then phenol is added dropwise, low-temp reaction is complete;Reaction solution is added dropwise to abundant crystallization in organic solvent D, is filtered, filter cake is with organic Solvent E mashing washing, it is dry, obtain 7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- Carboxylic acid dihydrochloride.
Wherein, organic solvent A used in step 1) reaction are as follows: dichloroethanes, carbon tetrachloride, tetrahydrofuran, DMF, first Benzene, preferably tetrahydrofuran;3- chlorine cephalo and the molar ratio of 4- (4- pyridyl group) -2- thyroidan are Instead The temperature is answered to beRadical initiator are as follows: cyclohexanone peroxide, dibenzoyl peroxide, tert-butyl hydroperoxide Hydrogen, azodiisobutyronitrile, azobisisoheptonitrile, preferably azodiisobutyronitrile;The input amount of radical initiator is 3- chlorine head Spore input amountPreferablyOrganic solvent B are as follows: petroleum ether, n-hexane, hexamethylene, preferably stone Oily ether.
Methylating reagent is iodomethane, dimethyl suflfate or dimethyl carbonate, preferably iodomethane in step 2) reaction.
Reaction dissolvent C described in step 3) reaction are as follows: methylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran, DMF, it is excellent It is selected as methylene chloride;The reagent for removing 7 protecting groups is phosphorus pentachloride, organic base and vicinal diamines;The organic base is front three Amine, triethylamine, pyridine;Preferably pyridine;The vicinal diamines are ethylene glycol, 1,2- propylene glycol, 1,2- butanediol, 2,3- fourth two Alcohol, preferably 1,2-PD;The reagent for removing 4 protecting groups is fortified phenol, preferably metacresol;Organic solvent D are as follows: stone Oily ether, n-hexane, hexamethylene, preferably petroleum ether;Organic solvent E are as follows: methylene chloride, chloroform, ethyl acetate, butyl acetate, Preferably methylene chloride.
The beneficial effects of the present invention are: the present invention is using 3- chlorine cephalo as initial reactant, to apply for the first time;3- chlorine cephalo It is the precursor of cefaclor key intermediate 7-ACCA, using than wide, yield is also bigger, and also compares in synthesis process 3- hydroxy-cepham has greater advantage;Under radical initiator catalysis, 3- chlorine cephalo and 4- (4- pyridyl group) -2- thyroidan are straight Condensation reaction is given birth in sending and receiving, thus the step of reducing activation, reaction safety, processing is convenient, belongs to environmental-friendly reaction type, Also avoid the generation of S-3 isomers;Quaternization reaction occurs again, obtains pyridiniujm;Then 4 are removed simultaneously using one kettle way Position and 7 protecting groups, carry out the reaction for removing two protecting groups successively in a reaction interval, to enormously simplify Reaction process, and the quality of reaction yield and product is improved, molar yield about 67.6% (in terms of 3- chlorine cephalo).The conjunction Have simple process at method, without harsh reaction condition the advantages that, be very suitable to industrialized production.
Specific embodiment
For the preparation method for making the clear Ceftaroline Fosamil intermediate provided by the invention of those skilled in the art, below It further illustrates in conjunction with the embodiments, but these embodiments are not to be construed as limiting the scope of the invention.
The preparation method of Ceftaroline Fosamil intermediate, reaction step are as follows:
Step 1) is drawn in nonpolar solvent (dichloroethanes, carbon tetrachloride, tetrahydrofuran, DMF, toluene) in free radical Hair agent (cyclohexanone peroxide, dibenzoyl peroxide, tert-butyl hydroperoxide, azodiisobutyronitrile, azobisisoheptonitrile) is urged Under change, condensation reaction, 3- chlorine cephalo and 4- (4- pyridyl group) -2- occur for 3- chlorine cephalo and 4- (4- pyridyl group) -2- thyroidan The molar ratio of thyroidan isReaction temperature is3- chlorine head is stirred to react into HPLC The peak area of spore is cooled to low temperature after reaction solution is concentrated into half volume less than 0.2%, filters the crystal of precipitation;With organic Solvent (petroleum ether, n-hexane, hexamethylene) washing, it is dry, obtain 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- Thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate hydrochloride;
Step 2) reacts the product of step 1) with methylating reagent (iodomethane, dimethyl suflfate or dimethyl carbonate), Obtain 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate iodine Compound;
The product that step 3) obtains step 2) be dissolved in organic solvent (methylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran, DMF in), phosphorus pentachloride is added, organic base is added dropwise under cryogenic conditions under inert gas protection, after fully reacting, then cool down To -40 DEG C, vicinal diamines are slowly added dropwise, after fully reacting;Then phenol is added dropwise, low-temp reaction is complete;Reaction solution is added dropwise to organic Abundant crystallization in solvent (petroleum ether, n-hexane, hexamethylene), filtering, filter cake organic solvent (methylene chloride, chloroform, acetic acid second Ester, butyl acetate) mashing washing, it is dry, obtain 7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- head Spore alkene -4- carboxylic acid dihydrochloride.
Embodiment 1
Step 1:7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid two The synthesis of benzene methyl hydrochloride:
24.2g3- chlorine cephalo and 7.8g4- (4- pyridyl group) -2- thyroidan is taken to be dissolved in 200ml dichloroethanes, nitrogen Gas shielded under the conditions of being protected from light, is slowly added to 0.82g azodiisobutyronitrile, after mixing evenly, is warming up to 83 in 30 minutes internal programs DEG C, the peak area of 3- chlorine cephalo is stirred to react into HPLC less than 0.2%;Reaction solution is transferred to depressurize on Rotary Evaporators and is steamed Fall the solvent of 1/2 volume, for reaction solution slow cooling to 0 DEG C, crystallization is overnight;It filters, filter cake is eluted with 400ml petroleum ether, dry; Obtain (7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole the sulfydryl] -3- cephem -4- carboxylic acid hexichol of compound 1 Methyl ester hydrochloride) 30.9g, molar yield 96.5%.
To 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid hexichol first Ester hydrochloride has carried out nmr analysis and characterization.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.52(s,2H);3.86 (d, J=18.0Hz, 1H);3.99 (d, J=18.0Hz, 1H);5.24 (d, J=6.0Hz, 1H);5.36 (d, J=6.0Hz, 1H);7.07-7.14(m,6H); 7.24-7.26(m,1H);7.30-7.34(m,3H);7.38-7.41(m,2H);7.44-7.48(m,4H);8.45 (d, J= 6.0Hz,2H);8.94 (d, J=6.0Hz, 2H);8.95(s,1H);9.01(s,1H).
Step 2:7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid The synthesis of benzhydryl ester iodide:
30.9g compound 1 is dissolved in 300ml THF, at room temperature in dropwise addition 10.6g iodomethane, room temperature in half an hour Under be stirred to react into HPLC the peak area of compound 1 less than 0.2%;Reaction solution is transferred to Rotary Evaporators by end of reaction It is upper to depressurize the solvent for evaporating 1/2 volume, then reaction solution is slowly dropped into the methylene chloride (400ml) stirred at low speed, is reacted For liquid slow cooling to 0 DEG C, crystallization is overnight;It filters, filter cake 400ml eluent methylene chloride, it is dry;Obtain (the 7- benzene second of compound 2 Acylamino- -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate iodide) 32.8g, molar yield 99.2%.
To 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid hexichol Methyl esters iodide have carried out nmr analysis and characterization.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.52(s,2H);3.86 (d, J=18.0Hz, 1H);3.99 (d, J=18.0Hz, 1H);4.35 (s, J=6.0Hz, 3H);5.26 (d, J=6.0Hz, 1H);5.35 (d, J=6.0Hz, 1H); 7.06-7.15(m,6H);7.22-7.24(m,1H);7.28-7.31(m,3H);7.33-7.35(m,2H);7.39-7.43(m, 4H);8.18 (d, J=6.0Hz, 2H);8.64 (d, J=6.0Hz, 2H);8.97(s,1H);9.08(s,1H).
Two hydrochloric acid of step 3:7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid The synthesis of salt:
32.8g compound 2 is dissolved in 300ml methylene chloride, 20.6g phosphorus pentachloride is added, nitrogen protection is protected from light item Under part, 5 DEG C are cooled to, in 9.8ml pyridine is added dropwise in half an hour, 0 DEG C is subsequently cooled to, is stirred to react into HPLC compound 2 Peak area less than 0.2%, be cooled to -40 DEG C rapidly, in being added dropwise 25ml1 in half an hour, 2- propylene glycol, be stirred to react to The peak area of imines chloromethylated intermediate is less than 0.3% in HPLC;In 90ml metacresol is added dropwise in half an hour, temperature is no more than 10 DEG C, the peak area of de- 7 protecting group intermediates is stirred to react into HPLC less than 0.2%;Fully reacting.Under the conditions of 0-2 DEG C, Reaction solution is added dropwise in 500ml petroleum ether, stirring and crystallizing, product filtering, three times with 200ml methylene chloride mashing washing, is obtained To compound 3 (7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride) 21.7g, molar yield: 81.3%.
To 7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride into Nmr analysis and characterization are gone.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.82 (d, J=18.0Hz, 1H);3.94 (d, J= 18.0Hz,1H);4.38 (s, J=6.0Hz, 3H);5.27 (d, J=6.0Hz, 1H);5.39 (d, J=6.0Hz, 1H);8.45 (d, J=6.0Hz, 2H);8.94 (d, J=6.0Hz, 2H);9.05(s,1H).
The specific synthetic route of embodiment 1 is as follows:
Embodiment 2
Step 1:7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid two The synthesis of benzene methyl hydrochloride:
24.2g3- chlorine cephalo and 7.8g4- (4- pyridyl group) -2- thyroidan is taken to be dissolved in 200ml carbon tetrachloride, nitrogen Gas shielded under the conditions of being protected from light, is slowly added to 0.58g tert-butyl hydroperoxide, after mixing evenly, is warming up in 30 minutes internal programs 88 DEG C, the peak area of 3- chlorine cephalo is stirred to react into HPLC less than 0.2%;Reaction solution is transferred on Rotary Evaporators and is depressurized The solvent of 1/2 volume is evaporated, for reaction solution slow cooling to 0 DEG C, crystallization is overnight;It filters, filter cake is eluted with 400ml n-hexane, is done It is dry;Obtain (7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole the sulfydryl] -3- cephem -4- carboxylic acid of compound 1 Benzhydryl ester hydrochloride) 31.1g, molar yield 97.1%.
To 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid hexichol first Ester hydrochloride has carried out nmr analysis and characterization.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.52(s,2H);3.86 (d, J=18.0Hz, 1H);3.99 (d, J=18.0Hz, 1H);5.24 (d, J=6.0Hz, 1H);5.36 (d, J=6.0Hz, 1H);7.07-7.14(m,6H); 7.24-7.26(m,1H);7.30-7.34(m,3H);7.38-7.41(m,2H);7.44-7.48(m,4H);8.45 (d, J= 6.0Hz,2H);8.94 (d, J=6.0Hz, 2H);8.95(s,1H);9.01(s,1H).
Step 2:7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid The synthesis of benzhydryl ester iodide:
31.1g compound 1 is dissolved in 300ml THF, at room temperature in half an hour be added dropwise 19.7g dimethyl suflfate, It is stirred to react the peak area of the compound 1 into HPLC at room temperature less than 0.2%;Reaction solution is transferred to rotation and steamed by end of reaction Decompression evaporates the solvent of 1/2 volume on hair instrument, is then slowly dropped into reaction solution in the methylene chloride (400ml) stirred at low speed, For reaction solution slow cooling to 0 DEG C, crystallization is overnight;It filters, filter cake 400ml eluent methylene chloride, it is dry;Obtain 2 (7- of compound Phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate iodide) 31.4g, molar yield 97.8%.
To 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid hexichol Methyl esters iodide have carried out nmr analysis and characterization.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.52(s,2H);3.86 (d, J=18.0Hz, 1H);3.99 (d, J=18.0Hz, 1H);4.35 (s, J=6.0Hz, 3H);5.26 (d, J=6.0Hz, 1H);5.35 (d, J=6.0Hz, 1H); 7.06-7.15(m,6H);7.22-7.24(m,1H);7.28-7.31(m,3H);7.33-7.35(m,2H);7.39-7.43(m, 4H);8.18 (d, J=6.0Hz, 2H);8.64 (d, J=6.0Hz, 2H);8.97(s,1H);9.08(s,1H).
Two hydrochloric acid of step 3:7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid The synthesis of salt
31.4g compound 2 is dissolved in 300ml THF, 20.6g phosphorus pentachloride is added, nitrogen protection is protected from light condition Under, 5 DEG C are cooled to, in 9.8ml pyridine is added dropwise in half an hour, 0 DEG C is subsequently cooled to, is stirred to react into HPLC compound 2 Peak area is cooled to rapidly -40 DEG C less than 0.2%, in 22ml ethylene glycol is added dropwise in half an hour, is stirred to react to the Central Asia HPLC The peak area of amine chloromethylated intermediate is less than 0.3%;In 100g phenol is added in half an hour, temperature is stirred to react no more than 10 DEG C The peak area of 7 protecting group intermediates is taken off into HPLC less than 0.2%;Fully reacting.Under the conditions of 0-2 DEG C, reaction solution is added dropwise Enter in 500ml n-hexane, stirring and crystallizing, product filtering, three times with 200ml chloroform mashing washing, obtains (the 7- amino-of compound 3 3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride) 20.1g, molar yield: 80.9%.
To 7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride into Nmr analysis and characterization are gone.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.82 (d, J=18.0Hz, 1H);3.94 (d, J= 18.0Hz,1H);4.38 (s, J=6.0Hz, 3H);5.27 (d, J=6.0Hz, 1H);5.39 (d, J=6.0Hz, 1H);8.45 (d, J=6.0Hz, 2H);8.94 (d, J=6.0Hz, 2H);9.05(s,1H).
Embodiment 3
Step 1:7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid two The synthesis of benzene methyl hydrochloride:
24.2g3- chlorine cephalo and 7.8g4- (4- pyridyl group) -2- thyroidan is taken to be dissolved in 200ml toluene, nitrogen is protected Shield, under the conditions of being protected from light, is slowly added to 1.25g dibenzoyl peroxide, after mixing evenly, is warming up to 95 in 30 minutes internal programs DEG C, the peak area of 3- chlorine cephalo is stirred to react into HPLC less than 0.2%;Reaction solution is transferred to depressurize on Rotary Evaporators and is steamed Fall the solvent of 1/2 volume, for reaction solution slow cooling to 0 DEG C, crystallization is overnight.It filters, filter cake is eluted with 400ml hexamethylene, dry; Obtain (7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole the sulfydryl] -3- cephem -4- carboxylic acid hexichol of compound 1 Methyl ester hydrochloride) 30.8g, molar yield 96.4%.
To 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid hexichol first Ester hydrochloride has carried out nmr analysis and characterization.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.52(s,2H);3.86 (d, J=18.0Hz, 1H);3.99 (d, J=18.0Hz, 1H);5.24 (d, J=6.0Hz, 1H);5.36 (d, J=6.0Hz, 1H);7.07-7.14(m,6H); 7.24-7.26(m,1H);7.30-7.34(m,3H);7.38-7.41(m,2H);7.44-7.48(m,4H);8.45 (d, J= 6.0Hz,2H);8.94 (d, J=6.0Hz, 2H);8.95(s,1H);9.01(s,1H).
Step 2:7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid The synthesis of benzhydryl ester iodide:
30.8g compound 1 is dissolved in 300ml DMF, at room temperature in half an hour be added dropwise 16.2g dimethyl carbonate, It is stirred to react the peak area of the compound 1 into HPLC at room temperature less than 0.2%;Reaction solution is transferred to rotation and steamed by end of reaction Decompression evaporates the solvent of 1/2 volume on hair instrument, is then slowly dropped into reaction solution in the methylene chloride (400ml) stirred at low speed, For reaction solution slow cooling to 0 DEG C, crystallization is overnight;It filters, filter cake 400ml eluent methylene chloride, it is dry;Obtain 2 (7- of compound Phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- diphenylmethyl carboxylate iodide) 32.2g, molar yield 99.0%.
To 7- phenylacetylamino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid hexichol Methyl esters iodide have carried out nmr analysis and characterization.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.52(s,2H);3.86 (d, J=18.0Hz, 1H);3.99 (d, J=18.0Hz, 1H);4.35 (s, J=6.0Hz, 3H);5.26 (d, J=6.0Hz, 1H);5.35 (d, J=6.0Hz, 1H); 7.06-7.15(m,6H);7.22-7.24(m,1H);7.28-7.31(m,3H);7.33-7.35(m,2H);7.39-7.43(m, 4H);8.18 (d, J=6.0Hz, 2H);8.64 (d, J=6.0Hz, 2H);8.97(s,1H);9.08(s,1H).
Two hydrochloric acid of step 3:7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid The synthesis of salt
32.2g compound 2 is dissolved in 300ml DMF, 20.6g phosphorus pentachloride is added, nitrogen protection is protected from light condition Under, 5 DEG C are cooled to, in 9.8ml pyridine is added dropwise in half an hour, 0 DEG C is subsequently cooled to, is stirred to react into HPLC compound 2 Peak area is cooled to rapidly -40 DEG C less than 0.2%, in half an hour be added dropwise 31ml 1,2- butanediol, be stirred to react to The peak area of imines chloromethylated intermediate is less than 0.3% in HPLC;In 90ml paracresol is added dropwise in half an hour, temperature is no more than 10 DEG C, the peak area of de- 7 protecting group intermediates is stirred to react into HPLC less than 0.2%;Fully reacting.Under the conditions of 0-2 DEG C, Reaction solution is added dropwise in 500ml hexamethylene, stirring and crystallizing, product filtering, three times with 200ml ethyl acetate mashing washing, is obtained To compound 3 (7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride) 21.5g, molar yield: 81.1%.
To 7- amino -3- [4- (1- methyl -4- pyridine) -2- thiazole sulfydryl] -3- cephem -4- carboxylic acid dihydrochloride into Nmr analysis and characterization are gone.
Nuclear magnetic data:1HNMR(500MHz,d6-DMS0)δ;3.82 (d, J=18.0Hz, 1H);3.94 (d, J= 18.0Hz,1H);4.38 (s, J=6.0Hz, 3H);5.27 (d, J=6.0Hz, 1H);5.39 (d, J=6.0Hz, 1H);8.45 (d, J=6.0Hz, 2H);8.94 (d, J=6.0Hz, 2H);9.05(s,1H).

Claims (8)

1. a kind of preparation method of Ceftaroline Fosamil intermediate, it is characterised in that: used starting material is 3- chlorine cephalo, instead Answer process the following steps are included:
Step 1) is in organic solvent A, under radical initiator catalysis, 3- chlorine cephalo and 4- (4- pyridyl group) -2- sulfydryl thiophene Condensation reaction occurs for azoles;The peak area of 3- chlorine cephalo is stirred to react into HPLC less than 0.2%, reaction solution is concentrated into a halfbody It is cooled to low temperature after product, filters the crystal of precipitation;It is washed with organic solvent B, final to obtain intermediate shown in following formula:
The organic solvent A are as follows: dichloroethanes, carbon tetrachloride, tetrahydrofuran, DMF or toluene;The organic solvent B are as follows: stone Oily ether, n-hexane or hexamethylene;The radical initiator are as follows: cyclohexanone peroxide, dibenzoyl peroxide, tert-butyl mistake Hydrogen oxide, azodiisobutyronitrile or azobisisoheptonitrile;
The molar ratio of the 3- chlorine cephalo and 4- (4- pyridyl group) -2- thyroidan is l:1.05~1.55;Reaction temperature is 50 DEG C~100 DEG C;The input amount of the radical initiator is the 2%~12% of 3- chlorine cephalo input amount;
Step 2) reacts the product of step 1) with methylating reagent, obtains intermediate shown in following formula:
The product that step 3) obtains step 2) is dissolved in organic solvent C, and phosphorus pentachloride is added, under inert gas protection, in Organic base is added dropwise under cryogenic conditions, after fully reacting, then is cooled to -40 DEG C, vicinal diamines are slowly added dropwise, after fully reacting;Then Phenol is added dropwise, low-temp reaction is complete;Reaction solution is added dropwise to abundant crystallization in organic solvent D, is filtered, filter cake is beaten with organic solvent E Plasm scouring finally obtains intermediate shown in following formula:
The vicinal diamines are as follows: ethylene glycol, 1,2- propylene glycol, 1,2- butanediol or 2,3- butanediol;The phenol is metacresol.
2. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 1, it is characterised in that: institute in step 2) The methylating reagent stated is iodomethane, dimethyl suflfate or dimethyl carbonate.
3. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 1, which is characterized in that institute in step 3) The organic solvent C stated are as follows: methylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran or DMF;The organic solvent D are as follows: petroleum Ether, n-hexane or hexamethylene;The organic solvent E are as follows: methylene chloride, chloroform, ethyl acetate or butyl acetate.
4. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 1, which is characterized in that step 3) is described Organic base are as follows: trimethylamine, triethylamine or pyridine.
5. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 1, which is characterized in that described organic molten Agent A is tetrahydrofuran;The organic solvent B is petroleum ether;The radical initiator is azodiisobutyronitrile.
6. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 1, it is characterised in that: the free radical The input amount of initiator is 9%~11%.
7. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 3, it is characterised in that: described organic molten Agent D is petroleum ether;The organic solvent E is methylene chloride.
8. a kind of preparation method of Ceftaroline Fosamil intermediate according to claim 4, it is characterised in that: described is organic Alkali is pyridine.
CN201710537327.6A 2017-07-04 2017-07-04 A kind of preparation method of Ceftaroline Fosamil intermediate Active CN107325114B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710537327.6A CN107325114B (en) 2017-07-04 2017-07-04 A kind of preparation method of Ceftaroline Fosamil intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710537327.6A CN107325114B (en) 2017-07-04 2017-07-04 A kind of preparation method of Ceftaroline Fosamil intermediate

Publications (2)

Publication Number Publication Date
CN107325114A CN107325114A (en) 2017-11-07
CN107325114B true CN107325114B (en) 2019-06-11

Family

ID=60199732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710537327.6A Active CN107325114B (en) 2017-07-04 2017-07-04 A kind of preparation method of Ceftaroline Fosamil intermediate

Country Status (1)

Country Link
CN (1) CN107325114B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108586494B (en) * 2018-01-04 2021-03-26 北京满格医药科技有限公司 Monocrystal of ceftaroline fosamil intermediate 1 and preparation method thereof
CN108440566A (en) * 2018-01-04 2018-08-24 北京满格医药科技有限公司 A kind of process for purification of Ceftaroline Fosamil intermediate 1
CN110878101A (en) * 2019-12-11 2020-03-13 华中药业股份有限公司 Novel method for preparing cefixime mother nucleus 7-AMOCA
CN115583957A (en) * 2022-11-02 2023-01-10 上海上药新亚药业有限公司 Methylation synthesis method of ceftaroline fosamil intermediate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1462275A (en) * 2000-08-10 2003-12-17 武田药品工业株式会社 Phosphonocephem compound
CN1675212A (en) * 2002-08-21 2005-09-28 贝林格尔英格海姆法玛两合公司 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2013112897A1 (en) * 2012-01-27 2013-08-01 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
CN104725425A (en) * 2015-04-09 2015-06-24 山东罗欣药业集团股份有限公司 Preparation method for ceftaroline fosamil
CN104910185A (en) * 2015-03-10 2015-09-16 国药集团致君(苏州)制药有限公司 Preparation method of ceftaroline fosamil intermediate parent nucleus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1462275A (en) * 2000-08-10 2003-12-17 武田药品工业株式会社 Phosphonocephem compound
CN1675212A (en) * 2002-08-21 2005-09-28 贝林格尔英格海姆法玛两合公司 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2013112897A1 (en) * 2012-01-27 2013-08-01 The Regents Of The University Of California Stabilization of biomolecules using sugar polymers
CN104910185A (en) * 2015-03-10 2015-09-16 国药集团致君(苏州)制药有限公司 Preparation method of ceftaroline fosamil intermediate parent nucleus
CN104725425A (en) * 2015-04-09 2015-06-24 山东罗欣药业集团股份有限公司 Preparation method for ceftaroline fosamil

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
卤代苯的芳香亲核取代反应及其反应机理探讨;王建功等;《天津大学硕士学位论文》;20090415;正文内容第19-20页
头孢菌素羧基保护基的脱除方法研究进展;邹晓斌等;《化工技术与开发》;20090930;第38卷(第9期);第1部分

Also Published As

Publication number Publication date
CN107325114A (en) 2017-11-07

Similar Documents

Publication Publication Date Title
CN107325114B (en) A kind of preparation method of Ceftaroline Fosamil intermediate
JP5774732B2 (en) Method for the synthesis of moxifloxacin hydrochloride
CN105175432B (en) Preparation method of cefditore
CN108947891B (en) Method for safely preparing pimavanserin and tartrate thereof by using triphosgene
CN104910185B (en) A kind of preparation method of Ceftaroline Fosamil intermediate parent nucleus
US20220315532A1 (en) Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof
CN110256338A (en) The method for being used to prepare PDE4 inhibitor
WO2017202365A1 (en) Preparation method for trifluoromethyl-substituted pyran derivative
CN116640088A (en) Preparation method of high-purity Lei Fen narasin
CA2930870C (en) Processes for the preparation of pyrimidinylcyclopentane compounds
WO2017202357A1 (en) Method for preparing trifluoromethyl-substituted pyran derivative
CN105254629B (en) A kind of preparation method of moxifloxacin hydrochloride
CN105859747A (en) Cefepime dihydrochloride preparation method suitable for industrial production
CN115322157A (en) Letemovir intermediate compound and preparation method and application thereof
KR20160027536A (en) Process for preparing an intermediate useful for the synthesis of silodosin
KR101673979B1 (en) Compound jk12a and preparation thereof
KR101485418B1 (en) A synthetic method of high purity mirtazapine
CN105131050A (en) Preparation method of chlorinating agent and method therewith for preparing sucralose
KR102702468B1 (en) Treprostinil monohydrate crystals and methods for preparation thereof
CN105330652B (en) A kind of preparation method of Afatinib
CN115536658B (en) Preparation method of moxifloxacin hydrochloride monohydrate
CN110577974B (en) Synthesis method of chiral 3-hydroxy-1, 2,3, 6-tetrahydropyridine
JP7377981B2 (en) Novel synthesis method for decrusin derivatives
KR101733084B1 (en) Process for preparing crystalline forms of silodosin
CN110003022A (en) A kind of synthetic method and its intermediate of Dapoxetine hydrochloride intermediate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant